Bioventus Inc. (NYSE:BVS - Get Free Report)'s share price fell 4.4% during trading on Friday . The company traded as low as $7.11 and last traded at $7.07. 18,819 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 372,452 shares. The stock had previously closed at $7.39.
Analyst Ratings Changes
A number of analysts have recently issued reports on the company. Cantor Fitzgerald initiated coverage on Bioventus in a report on Monday. They issued an "overweight" rating and a $12.00 target price for the company. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a "buy" rating in a report on Wednesday, May 7th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th.
View Our Latest Report on Bioventus
Bioventus Price Performance
The stock has a market cap of $572.54 million, a P/E ratio of -11.43 and a beta of 0.84. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company's fifty day simple moving average is $6.70 and its 200-day simple moving average is $8.50.
Hedge Funds Weigh In On Bioventus
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its holdings in shares of Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after buying an additional 1,786 shares during the last quarter. GAMMA Investing LLC raised its position in Bioventus by 3,228.7% in the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock worth $53,000 after purchasing an additional 5,618 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Bioventus by 23,761.5% during the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock worth $57,000 after buying an additional 6,178 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Bioventus during the 4th quarter worth $75,000. Finally, Quantbot Technologies LP bought a new position in Bioventus in the fourth quarter valued at about $103,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.
Bioventus Company Profile
(
Get Free Report)
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Featured Articles
Before you consider Bioventus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.
While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
